404 related articles for article (PubMed ID: 35352522)
21. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
22. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract][Full Text] [Related]
23. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
[TBL] [Abstract][Full Text] [Related]
24. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
25. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
Busetto GM; Del Giudice F; Maggi M; De Marco F; Porreca A; Sperduti I; Magliocca FM; Salciccia S; Chung BI; De Berardinis E; Sciarra A
World J Urol; 2021 Jun; 39(6):1869-1877. PubMed ID: 32681273
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
28. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
[TBL] [Abstract][Full Text] [Related]
29. Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Pellegrino F; Stabile A; Sorce G; Mazzone E; Cannoletta D; Cirulli GO; Quarta L; Leni R; Robesti D; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2024 Apr; 84(5):473-478. PubMed ID: 38149793
[TBL] [Abstract][Full Text] [Related]
30. Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?
Anastay V; Gondran-Tellier B; McManus R; Delonca R; Akiki A; Gaillet S; Delaporte V; Andre M; Daniel L; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
Abdom Radiol (NY); 2020 Dec; 45(12):4160-4165. PubMed ID: 32902661
[TBL] [Abstract][Full Text] [Related]
31. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
[TBL] [Abstract][Full Text] [Related]
32. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Pellegrino F; Stabile A; Mazzone E; Sorce G; Barletta F; De Angelis M; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2022 Sep; 82(12):1170-1175. PubMed ID: 35538401
[TBL] [Abstract][Full Text] [Related]
33. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
35. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
36. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
[TBL] [Abstract][Full Text] [Related]
37. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Witjes JA; van Melick HHE; Somford DM
BJU Int; 2023 Mar; 131(3):313-320. PubMed ID: 35993590
[TBL] [Abstract][Full Text] [Related]
38. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men.
Venderink W; van Luijtelaar A; van der Leest M; Barentsz JO; Jenniskens SFM; Sedelaar MJP; Hulsbergen-van de Kaa C; Overduin CG; Fütterer JJ
BJU Int; 2019 Nov; 124(5):775-784. PubMed ID: 31237388
[TBL] [Abstract][Full Text] [Related]
40. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]